Connect with us

Biotechnology

Active Biotech Stocks To Watch As Markets Flirt With New Highs

A. Lawrence

Published

on

biotech stocks to watch

Biotech stocks is often regarded as safe due to the simple fact that it is a sector that has grown across the board for quite some time. However, in addition, the biotech sector has the potential to generate handsome gains if an investor ends up choosing the right stock.

Investors need to watch the market closely and be aware of the latest news from the sector in order to make the best choices. Here is a look at 3 biotech stocks that turned heads in the biotech sector this week.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech (PMCB) is in the prep phase of clinical trials and readying to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.

“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”

As one report puts it, “Clinical trials are essential for the development of new treatments, and PharmaCyte will enter this upcoming trial with two essential goals in mind—the future of its pancreatic cancer treatment and the future of its technology.”

For more on PharmaCyte, Click Here

VIVUS (VVUS)

The first biotech stock to consider here is that of VIVUS, Inc. (NASDAQ:VVUS), which has rallied on Wednesday on the back of a major announcement from the company. The stock rallied by 3% this morning in premarket trade after the results were announced from the Phase 1 clinical trial of its product Qsymia. The medicine in question is a capsule and is meant for people who suffer from binge eating disorder.

It should be noted that medicine is currently approved in the United States when used by people in order to reduce calories in their diets. It is a major development for VIVUS and it is no surprise that the stock rallied today.

Diffusion Pharmaceuticals (DFFN)

The other biotech stock that is worth including in the watch list is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), which made solid gains yesterday on the back of the announcement of positive preliminary data from the Phase 3 clinical trial of Trans Sodium Crocetinate (TSC). The medicine is meant for treating inoperable glioblastoma and in the results, it has been revealed that patients recorded a median survival duration of as long as 14.3 months.

Historically, the standard survival duration is only 9.2 months. The results triggered a rally in the stock and the Diffusion stock soared by as much as 67.60%.

list of healthcare stocks to watch

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading
Click to comment

Biotechnology

2 Biotech Stocks Turning Heads After Key Developments This Quarter

Joe Samuel

Published

on

biotech stocks to watch today

There are very few sectors in the stock market that have consistently produced winning trades. You might be able to count such sectors on one hand. Biotech is certainly among those sectors due to the emergence of highly innovative companies. These firms tend to create new avenues of creation to address unmet medical needs.

There are plenty of promising companies in the sector but it is necessary for an investor to do research thoroughly. It makes finding the best biotech stocks a bit easier. Though no one’s guaranteed a win, sifting out bad stocks is the key. One must watch the market closely to come across promising biotech stocks. Here is a look at two biotech stocks that are worth watching.

Biotech Stocks To Watch: Moleculin Biotech (MBRX)

The first biotech stock to consider is that of Moleculin Biotech Inc (NASDAQ:MBRX), which made some gains on Wednesday on the back of positive interim results for one of its products. The company, which is involved in manufacturing medicines meant for extremely resistant tumors, released data with regards to its acute myeloid leukaemia medicine annamycin.

top biotech stocks to buy

Moleculin revealed highly positive interim data from the Phase ½ clinical study of the medicine and naturally, it has resulted in a lot of excitement in the market with regards to the stock. The stock rose by as much as 2% on the back of the news in yesterday’s trading session. It is one of the key biotech stocks to keep an eye on over the coming days.

Biotech Stocks To Watch: Eyepoint Pharmaceuticals (EYPT)

The other biotech stock that has recorded impressive gains on the market today is the Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) stock. On Wednesday, the company announced an important deal with regard to dexamethasone intraocular suspension 9% (DEXYCU). Eyepoint announced that it has managed to reach an agreement with one of the biggest players in the U.S. integrated delivery systems.

[Read More] 3 Pharma Stocks To Watch In December 2019

The deal is for two years and the other party is going to offer DEXYCU in its aforesaid systems. It is a major boost for Eyepoint and it has resulted in 5% to close at $1.54 in Wednesday’s trading session.

best biotech stocks to watch today

Continue Reading

Biotechnology

2 Biotech Stocks to Watch As The Sector Hits New High

Joe Samuel

Published

on

best biotechnology stocks to buy sell

The biotech sector has thrown plenty of winners over the course of the last decade or so and if experts are to be believed then it is going to continued to do so for the foreseeable future. Great advancements are being made in the biotech industry and many companies are working on a highly advanced product.

In such a situation, it is imperative for an intelligent investor to look for companies worth investing in. One should watch the latest developments in the sector and track specific companies closely. Here is a look at two biotech stocks that are worth watching.

Neoleukin Therapeutics

top biotech stocks to watch list

The first biotech stock to watch is that of Neoleukin Therapeutics Inc (NLTX), which has managed to gain significantly over the past two weeks. On November 13, the company released its third-quarter results and since then it has rocketed by as much as 75%. The Canadian company made a loss of $59.1 million in the quarter, which worked out to $2.26 per share.

The company is a biopharmaceutical company that is involved in immunotherapies using de novo protein design technology. The company’s lead product candidate is NL-201, which is an amalgamation of both IL-2 and IL-15 and helps in removing alpha receptor binding.

Verastem

healthcare stocks to buy now

The other biotech stock that is worth watching is Verastem Inc (NASDAQ:VSTM). It made significant gains over the past week. On Monday, the company announced that it has submitted a Marketing Authorization Application for its product COPIKTRA to the European Medicines Agency.

COPIKTRA is a phosphoinositide 3-kinase. It’s meant for patients suffering from refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).

The company is seeking approval for the same in the European market. Verastem stated that it has seen significant improvement in patients who used the product. The stock rocketed by as much as 60% after the news broke and remains one of the stocks to watch this week.

Continue Reading

Biotechnology

2 Biotech Stocks To Watch Gaining Momentum Right Now

Joe Samuel

Published

on

best biotech stocks to watch

Biotech is a sector that has grown significantly over the past decade or so and continues to hold a lot of promise if market experts are be believed. Hence, it is no surprise that investors are almost always on the lookout for the next winners from among the hundreds of penny stocks in the market.

However, if one has to identify a promising stock, then he has to watch the market closely and do his own research quite thoroughly. Here is a look at two biotech stocks that should be watched closely by all investors.

Oramed Pharmaceuticals Hits New Highs

The first biotech stock that should be put into the watch list is that of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). The company, which is engaged in developing oral drug delivery systems, announced highly positive results from the Phase 2b trial of its product ORMD-0801.

The product in question is an oral insulin treatment and if it is eventually approved then it would become the very first orally administered insulin product. Hence, the optimism around the product and the Oramed stock is perfectly understandable.

Over the course of the past two weeks, the stock has gained by as much as 135%. Moreover, the stock made a new 52-week high of $5.80 in Monday’s trading session.

Clearside Biomedical Jumps 70% in 2-Week

best biotech stocks to watch today

The other biotech stock that has enjoyed an impressive rally in recent times is that of Clearside Biomedical Inc (NASDAQ:CLSD). The company developed a specially designed suprachoroidal space (SCS) microinjection platform. It helps administer medicines to the eyes. One of the most important medicines in its pipeline, Xipere, treats macular edema. The disease can seriously affect a person’s eyesight.

Earlier this year, the company announced that it had decided to postpone Xipere due to issues with its contractors. However, a complete response letter from the FDA in October revealed that the regulatory body needed more information about the medicine. The information demanded did not include anything that was related to the effectiveness of the medicine. The stock has gained 70% over the past two weeks.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com